<DOC>
	<DOCNO>NCT01563562</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetic profile bardoxolone methyl follow single oral dose 20 mg bardoxolone methyl subject mild , moderate , severe hepatic impairment , compare healthy volunteer .</brief_summary>
	<brief_title>Single-Dose , Open-Label Pharmacokinetic Study Bardoxolone Methyl Subjects With Mild , Moderate , Severe Hepatic Impairment Normal Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>All subject 1 . Male female subject 18 70 year , inclusive ; must meet follow criterion include study : 2 . Willing practice method birth control ( male partner childbearing potential female childbearing potential ) screening , take study drug least 30 day last dose study drug ingest ; 3 . Female subject childbearing potential must nonpregnant nonlactating negative serum pregnancy test result enrollment study ; 4 . Body mass index ( BMI ) 18 37 kg/m2 ; 5 . Willing able give write informed consent study participation ; 6 . Willing able cooperate aspect protocol . Subjects hepatic impairment 7 . Have document evidence hepatic cirrhosis biopsy , nuclear scan , CT , MRI , ultrasound , clinically acceptable method ; must meet follow criterion include study : 8 . Be classify ChildPugh class A ( mild ) , B ( moderate ) , C ( severe ) . ( See Appendix A ChildPugh system . ) All subject 1 . Participated another clinical trial investigational drug ( medical device ) within 30 day Study Day 1 , currently participate another trial investigational drug ( medical device ) ; follow condition characteristic must exclude study : 2 . Known hypersensitivity component formulation study drug , bardoxolone methyl ; 3 . Any medical dental procedure , matter minor , plan anticipate occur conduct study ; 4 . History drug alcohol abuse dependence within last year ; 5 . Donation receipt blood blood component within 4 week prior Study Day 1 . The investigator instruct subject participate study donate blood blood component 4 week completion study ; 6 . Abnormal screen ECG interpret investigator clinically significant ; 7 . A positive test drug ( ) abuse ( ethanol , amphetamine , benzodiazepine , barbiturate , cocaine , opiates , cannabinoids ) screen Day 1 visit , unless positive drug screen subject hepatic impairment prescription drug approve principal investigator ; 8 . Female subject plan pregnancy pregnant lactating ; 9 . Deemed investigator inappropriate study , include subject unable communicate investigator due language problem , poor mental development , impaired cerebral function ; 10 . Any concurrent clinical condition judgment investigator could either potentially pose health risk subject involve study could potentially influence study outcome ; 11 . Positive test result human immunodeficiency virus type 1 2 antibody screening ; 12 . Have estimate creatinine clearance &lt; 60 mL/min Study Day 1 use CockcroftGault equation ( Appendix B ) ; 13 . Any condition possibly affect absorption , distribution , metabolism excretion drug may confound analysis conduct study ( example : previous surgery gastrointestinal tract include removal part stomach , bowel , liver , gall bladder , pancreas , venacaval shunt , transjugular intrahepatic portosystemic shunt ] ) . Subjects hepatic impairment 14 . Sustained systolic blood pressure &gt; 160 mmHg &lt; 100 mmHg diastolic blood pressure &gt; 100 mmHg screen baseline measure 5 minute sit position ; follow condition characteristic must exclude study : 15 . A pulse rate rest sit position &lt; 45 bpm &gt; 105 bpm ; 16 . Documented evidence primary biliary cirrhosis ; 17 . Evidence recent ( two month less ) current gastrointestinal bleeding ; 18 . Platelet count &lt; 50,000 &gt; 450,000 . Subjects normal hepatic function 19 . Sustained systolic blood pressure &gt; 150 mmHg &lt; 100 mmHg diastolic blood pressure &gt; 95 mmHg screening measure 5 minute sit position ; follow condition characteristic must exclude study : 20 . A pulse rate rest sit position &lt; 45 bpm &gt; 100 bpm ; 21 . Evidence history concurrent clinically significant allergic ( except untreated , asymptomatic , seasonal allergy time dose administration ) , hematological , endocrine , immunological , renal , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease judgment investigator could potentially either pose health risk subject study influence study outcome ; 22 . Evidence hepatic biliary dysfunction include elevation total bilirubin , direct bilirubin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gamma glutamyl transpeptidase ( GGT ) , lactate dehydrogenase ( LDH ) , alkaline phosphatase level great upper limit normal ( ULN ) ; 23 . Positive test result hepatitis B virus antibody , hepatitis C virus antibody screening ; 24 . Use need systemic drug ( ) include vitamin herbal preparation drug use contraception , within 10 day Study Day 1 study ; 25 . Use aspirin , nonsteroidal antiinflammatory agent , acetaminophen within 5 day prior ingestion study drug ; use aspirin nonsteroidal anti inflammatory agent ( acetaminophen ) allow isolated episode pain discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>